Among patients with uterine cancers, pembrolizumab, a common PD-1 inhibitor, showed a pooled HR of 0.66 for OS (95% CI: 0.57–0.75, p <.001; Supplementary Figure 2B) (21, 24). Here, PDCD1 is linked to uterine cancer.